ATOUSA GHORBANI

Dr. ATOUSA GHORBANI

Department of Genetics, Islamic Azad University North Tehran Branch, Tehran, Tehrān, Iran
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2022 in International Immunopharmacology
Verified
Journal Article
Closed access
MRMitra Ranjbar
Mitra Ranjbar
ARAli Rahimi
Ali Rahimi
ZBZeinab Baghernejadan
Zeinab Baghernejadan
AGATOUSA GHORBANI
ATOUSA GHORBANI
HKHossein Khorramdelazad
Hossein Khorramdelazad

25 December 2023 in Cancer Genetics
Verified
Journal Article
Closed access
AGATOUSA GHORBANI
ATOUSA GHORBANI
FHFatemeh Hosseinie
Fatemeh Hosseinie
SSSaeideh Khorshid Sokhangouy
Saeideh Khorshid Sokhangouy
MIMuhammad Islampanah
Muhammad Islampanah
FKFatemeh Khojasteh-Leylakoohi
Fatemeh Khojasteh-Leylakoohi
AAAmir Avan
Amir Avan

8 July 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
MKMahsa Karami
Mahsa Karami
PSPantea Majma Sanaye
Pantea Majma Sanaye
AGATOUSA GHORBANI
ATOUSA GHORBANI
RARoshanak Amirian
Roshanak Amirian
PGPouya Goleij
Pouya Goleij
ZIZhila Izadi
Zhila Izadi
Parkinson’s disease (PD) is a neurodegenerative disease with severe movement problems. Current treatments mainly focus on symptom management by reducing dopaminergic pathways in the brain. Despite these therapies, ongoing disease progression undermines the effectiveness of prevalent approaches, necessitating exploring alternative methods anchored on genetic factors, notably the leucine-rich repeat kinase 2 (LRRK2) gene. Exploring LRRK2 gene pathogenesis has highlighted various mechanisms that may contribute to treating PD, including protein accumulation, altered cytoskeletal dynamics, neuro-inflammation, autophagy, and mitochondrial dysfunction. Based on the findings, there is an actual correlation between elevated levels of LRRK2 and the biomarkers and assays of PD. Furthermore, research results have suggested inhibiting LRRK2 as a therapeutic intervention targeting pathogenic mechanisms with varying degrees of efficacy. Our review wants to understand how LRRK2 works in the body and its relationship with the occurrence of PD by providing biochemical evidence, LRRK2 gene mutations and pathology, and the role of this gene in the immune system. We also discuss targeted therapies such as kinase inhibitors and Proteolysis targeting chimera and the application of using the LRRK2 protein to diagnose PD and develop bioassay designs. Finally, we mention the clinical trials conducted and the challenges and safety required.

23 March 2023 in Archives of Virology
Verified
Journal Article
Open access
PDF file
FRFateme Zabihi Rizi
Fateme Zabihi Rizi
AGATOUSA GHORBANI
ATOUSA GHORBANI
PZParnia Zahtab
Parnia Zahtab
NDNiloufar Naderi Darbaghshahi
Niloufar Naderi Darbaghshahi
NANioosha Ataee
Nioosha Ataee
MHMasoud Hooshmand
Masoud Hooshmand
Coronavirus disease 2019 (COVID-19) is a lethal disease caused by the coronavirus SARS-CoV-2, which can result in a broad clinical spectrum of respiratory symptoms. While many clinical risk factors such as concomitant chronic diseases play roles in the pathophysiology of COVID-19, genetic predisposition factors have not been widely studied. The aim of this study was, therefore, to evaluate the relationship between some singlenucleotide polymorphisms (SNPs) of the human genes TYK2 and ACE2 and the severity of SARS-CoV-2 infection. Genomic DNA was isolated from 200 SARS-CoV-2-infected individuals with severe (n = 100) or mild (n = 100) disease. Owing to the importance of ACE2 and TYK2 genes in regulating the immune response to SARS-CoV-2 infection, TYK2 gene SNPs, i.e. rs2304255, rs2304256, rs12720270, and rs12720354 and ACE2 rs382746 variants, were genotyped in the samples. To confirm the results, the expression of different TYK2 genotypes was investigated using real-time PCR. The presence of the nucleotide T at the locus rs2304255 was shown to be a risk factor linked to disease severity (OR [95% CI] = 3.2485 [2.1554–4.8961]). Similarly, the presence of A at the locus rs12720354 increased the risk of severity (OR [95% CI]) = 3.9721 [2.6075–6.0509]). In contrast, the presence of A at the loci rs2304256 and rs12720270 was observed to reduce the severity risk (OR [95% CI] = 0.2495 [0.1642–0.3793] and 0.1668 [0.1083–0.2569], respectively). Real-time PCR results also demonstrated that the expression level of TYK2 in samples with the TT genotype of rs2304255 and the AA genotype of rs12720354 and in samples with the GG genotype of rs12720207 was significantly lower than in those with other genotypes. The results of this study suggest that TYK2 SNPs might be utilized to identify individuals who are at risk for severe COVID-19, in order to better manage their health care. It is predicted that the presence of some alleles (T in rs2304255, A in rs12720354, and G in rs12720207) of TYK2 can affect COVID-19 severity by reducing TYK2 expression and thereby affecting the regulatory role of TYK2 in the immune response.

20 November 2025 in Nutrition & Metabolism
Verified
Journal Article
Open access
PDF file
RZRasa Zafari
Rasa Zafari
NGNooshin Goudarzi
Nooshin Goudarzi
AKAmirhossein Kamroo
Amirhossein Kamroo
MTMahdi Falah Tafti
Mahdi Falah Tafti
AGATOUSA GHORBANI
ATOUSA GHORBANI
MNMarjan Nassiri-Asl
Marjan Nassiri-Asl
Neurodegenerative diseases (NDDs) like Alzheimer’s disease (AD) and Parkinson’s disease (PD) are growing global health concerns characterized by progressive cognitive and motor impairments. Recent studies have reported the role of gut microbiota and its interaction with the microbiome-gut-brain axis (MGBA) in these disorders. Dietary polyphenols possess antioxidant and antiinflammatory properties, which might modulate gut microbiota and attenuate the progression of these NDDs by acting on MGBA. This systematic review evaluates the effects of polyphenols on gut microbiota, their metabolites, and gut microbiota-related mechanisms in NDDs. Following PRISMA guidelines, a comprehensive literature search was conducted across Embase, PubMed, Scopus, and Google Scholar databases. Studies investigating the effects of polyphenols on gut microbial metabolites and composition in NDDs were reviewed. Data were extracted on study design, interventions, and outcomes, and quality was assessed using SYRCLE’s risk of bias tool. Twenty-six animal studies met the inclusion criteria. Polyphenols favored microbial beneficial changes, increased short-chain fatty acids (SCFAs), and reduced neuroinflammation by modulating inflammatory cytokine profiles (IL-1β, TNF-α, and IL-6 reduction). In NDD animal models, memory and motor functions were observed to have improved, likely due to reduced oxidative stress, as well as decreased amyloid accumulation and improved gut and brain integrity. The interventions enriched beneficial genera (Bacteroidetes, Bifidobacterium, Lactobacillus, Rikenellaceae, and Alloprevotella) and reduced detrimental groups (Helicobacter, Bacteroidaceae, Rikenella, and Prevotella). The evidence suggests polyphenols may influence the gut microbiota and, in turn, alleviate NDD symptoms. However, we need to confirm this in more studies, especially in human studies.

18 April 2024 in BMC Public Health
Verified
Journal Article
Open access
PDF file
MVMohammad Moein Vakilzadeh
Mohammad Moein Vakilzadeh
RKReza Khayami
Reza Khayami
DDDanyal Daneshdoust
Danyal Daneshdoust
RMReza Moshfeghinia
Reza Moshfeghinia
FSFarzad Sharifnezhad
Farzad Sharifnezhad
RMReihaneh Alsadat Mahmoudian
Reihaneh Alsadat Mahmoudian
Background: The prevalence of tobacco use among various cancer types in Iran remains a significant concern, necessitating a comprehensive analysis to understand the extent and patterns of consumption. This study aimed to systematically review and analyze existing literature to delineate the prevalence of tobacco use across different cancer types in Iran, thereby providing a robust basis for future interventions and policy formulations. Methods: Adhering to the PRISMA guidelines, we conducted a systematic review and meta-analysis of literature available in PubMed and Scopus databases. The initial search identified 351 records, out of which 44 studies were selected based on their relevance and design. These studies spanned various time frames, starting from the 2001s up until 2022, and encompassed diverse geographical locations and cancer types in Iran. To avoid bias and potential data overlap, we opted to incorporate a single comprehensive study from the Golestan Cohort, encompassing all data, while excluding 10 other studies. Our final analysis incorporated data from 34 studies, which accounted for 15,425 patients and 5,890 reported smokers. Statistical analyses were performed to calculate the overall proportion of tobacco consumption and to conduct subgroup analyses based on different variables such as cancer types, gender, geographical locations, and types of tobacco used. Results: The analysis revealed a substantial prevalence of tobacco use among cancer patients in Iran, with an overall consumption rate of 43%. This rate varied significantly, ranging from 10 to 88% across individual studies. Subgroup analyses further highlighted disparities in tobacco consumption rates across different demographics, geographic areas, and cancer types. Notably, the ‘ever’ smokers category exhibited the highest prevalence of tobacco use. The study also identified a worrying trend of high cigarette smoking rates, along with variable consumption patterns of other forms of tobacco, including waterpipe, ‘Naas’, and ‘Pipe’. Conclusions: This systematic review and meta-analysis underscores a significant association between tobacco consumption and various cancer types in Iran, with a prevalence rate among cancer patients being three times higher than the average Iranian population. The findings indicate substantial heterogeneity in tobacco use patterns, emphasizing the need for targeted interventions to address this pressing health issue. The study serves as a critical resource for shaping future policies and strategies aimed at curbing tobacco use and mitigating its adverse effects on cancer prevalence in Iran.